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patient’s blood culture subsequently revealed persistent methicillin-resistant Staphylococcus
aureus (MRSA) bacteremia despite the administration of vancomycin or teicoplanin monother-
apy. Gallium inflammation scan and magnetic resonance image of the spine disclosed osteomy-
elitis and discitis at the level of L4e5. Surgical debridement was not feasible in this debilitated
patient. Because of the creeping minimal inhibitory concentration of vancomycin of the caus-
ative isolate (1.5 mg/mL) and clinical failure with glycopeptide monotherapy, we changed the
antibiotic therapy to a fosfomycin and teicoplanin combination therapy. The patient showed
improved clinical response in terms of her enhanced consciousness as well as subsidence of
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Vancomycin-tolerant MRSA osteomyelitis 601hypernatremia), it combined with a glycopeptide may be an alternative therapy for invasive
refractory MRSA infections.
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Staphylococcus aureus is the most common causative agent
of hematogenous vertebral osteomyelitis among adults,
accounting for over 60% of cases.1 Emergence of the
methicillin-resistant S. aureus (MRSA) strain has further
complicated management of patients with vertebral oste-
omyelitis. The increasing minimal inhibitory concentration
(MIC) of MRSA now accounts for a large proportion of
invasive S. aureus infections.2 MRSA-related infections
often result in higher mortality rates and longer duration of
hospitalization.3,4 The Clinical and Laboratory Standards
Institute lowered the susceptibility breakpoint of S. aureus
from 4 mg/mL to 2 mg/mL, teicoplanin 8 mg/mL and fosfo-
mycin 64 mg/mL.5 Vancomycin or teicoplanin has been the
antibiotic of choice for MRSA bacteremia. However, many
alternative agents and combination therapies are consid-
ered as the salvage therapy of MRSA bacteremia when
vancomycin treatment fails.6,7
Fosfomycin is a phosphoenolpyruvate analog produced
by Streptomyces that inhibits enolpyruvate transferase,
which prevents the formation of the peptidoglycan cell
wall.8 In vitro studies have confirmed the effectiveness of
fosfomycin in combination with other antistaphylococcal
agents, including vancomycin and teicoplanin, when con-
ventional glycopeptide therapy fails.9 Moreover, high con-
centrations of fosfomycin in bone tissue have been proved
to be effective for treating osteomyelitis.10
We describe a case of lumbar osteomyelitis and discitis
with persistent MRSA bacteremia refractory to vancomycin
treatment. The patient was treated successfully with a
combination therapy of fosfomycin and teicoplanin.Case report
An 85-year-old female had a history of type 2 diabetes
mellitus and was bedridden following a cerebral vascular
accident. She had recurrent multiple pressure sores over
lumbosacral areas. On admission, she was presented with
fever and disturbed consciousness for 2 days. Physical ex-
amination revealed blood pressure of 89/68 mmHg and
heart rate of 98 beats per minute. She had moderate res-
piratory distress, with a respiratory rate of 22 breaths per
minute, and a body temperature of 39.5C. The patient had
multiple pressure sores over the lumbosacral and bilateral
ankles area. Her white blood cell count was 26,960/mL,
with 85% neutrophils and 9% band forms; platelet count
125,000/mL; and hemoglobin concentration 11.5 g/dL. The
patient’s biochemistry data were as follows: blood urea
nitrogen 26 mg/dL, creatinine 1.26 mg/dL, randomized
glucose 186 mg/dL, sodium 143 mmol/L, and potassium3.3 mmol/L. Serum level of C-reactive protein (CRP) was
19.31 mg/dL. Urinalysis showed pyuria and bacteriuria. Her
chest X-ray showed no evidence of active lung infection.
Brain computed tomography revealed no intracerebral
hemorrhage or evidence of newly onset cerebral infarction.
Abdominal sonography revealed no biliary tract lesion. The
empirical antibiotic of cefoperazone/sulbactam (2/1 g) was
administered intravenously (i.v.) every 12 hours.
On the 4th admission day, urine culture yielded Escher-
ichia coli and blood culture revealed MRSA. The antibiotic
treatment was changed to ertapenem 1 g i.v. every 24 hours
and vancomycin 1 g i.v. drip for 1 hour every 12 hours to
cover both agents based on our laboratory susceptibility
test (vancomycin MIC: 1.0 mg/mL by E test). One week
later, blood cultures yielded MRSA (vancomycin MIC:
1.5 mg/mL by E test) repeatedly. Her urinalysis showed no
pyuria in repeated tests and urine culture was negative.
Echocardiography disclosed no evidence of infective
endocarditis. Vancomycin was changed to teicoplanin (MIC:
1.0 mg/mL by E test) 400 mg once a day i.v. due to renal
function deterioration and persisted bacteremia. MRSA
bacteremia persisted despite a 2-week course of intrave-
nous teicoplanin therapy. Erythrocyte sedimentation rate
(ESR) was 91 mm/h and CRP was 11.7 mg/dL.
Magnetic resonance imaging of the L-spine indicated
osteomyelitis and discitis at L4 and L5, with the involve-
ment of bilateral psoas muscles and epidural abscess with
low signal intensity on T1-weighted image and low-to-
isointense signal on T2-weighted images, enhancement
after gadolinium injection (Fig. 1A) and transverse view
(Fig. 1B). Surgical debridement was not performed on the
patient due to her poor performance status as well as the
refusal of the patient’s family. The antibiotic regimen was
changed to a combination therapy comprising fosfomycin
4 g i.v. every 6 hours and teicoplanin 400 mg once daily.
After commencing this combination regimen, blood cul-
tures became sterile 1 week later.
The patient received a 5-week course of fosfomycin plus
teicoplanin combination therapy. Serum ESR and CRP
decreased to 35 mm/h and 2.1 mg/dL, respectively. The
patient was discharged and in our outpatient clinic received
a combination therapy comprising intramuscular injections
of teicoplanin 400 mg twice a week, oral fusidic acid 500 mg
every 8 hours, and rifampicin 300 mg orally every 12 hours
for 2 months. She recovered well and there was no bacte-
rial growth in repeated blood cultures.
Discussion
Vancomycin is the drug of choice for invasive MRSA infec-
tion. Due to the high mortality rate associated with MRSA
infections, many alternative agents and combination
Figure 1. Spinal T2-weighted magnetic resonance images revealed (A) osteomyelitis and discitis at L4 and L5 with gadolinium
enhancement (arrow), and (B) epidural abscess and psoas muscle abscess (arrow).
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tolerant strains, clinical treatment failure, or severe
adverse effects.6,7 The minimal bactericidal concentration
(MBC) determination by the Clinical and Laboratory Stan-
dards Institute for the causative S. aureus isolate of this
patient was 48 mg/mL, and the MBC/MIC ratio was  32.
Therefore, a combination therapy may be considered for
such tolerant strains.6,9,11 Moise et al12 have proved that
MRSA bloodstream isolates from patients treated with
vancomycin may demonstrate reduced susceptibility and
increased tolerance to vancomycin in vitro. For MRSA in-
fections with reduced vancomycin efficacy, consideration
may be given to alternative anti-MRSA agents or combina-
tion therapies.12,13
Fosfomycin is a phosphoenolpyruvate analogue and has
been shown to have reliable efficacy against S. aureus.11
In vitro studies confirmed the synergistic effect of fosfomy-
cin in combination with other anti-Staphylococcus agents,
including vancomycin, teicoplanin, and rifampicin, when
conventional glycopeptide therapy fails.11,12 Fosfomycin can
penetrate bone tissue and maintain high concentrations,
which make it effective for treating osteomyelitis.10
Because the patient had lumbar osteomyelitis, discitis,
and epidural abscess with persistent MRSA bacteremia after
monotherapy with vancomycin or teicoplanin, a combina-
tion of fosfomycin plus teicoplanin i.v. was given to our
patient during hospitalization. The effectiveness of this
combination therapy was shown by the eradication of S.
aureus bacteremia in repeated blood cultures and a sub-
stantial decline in the levels of CRP and ESR.
Although vancomycin is still the drug of choice for MRSA
bacteremia, the tolerance or creeping MIC of vancomycin
is a major issue about treatment outcome.11e14 Among
the isolates with higher MICs within the susceptible range
( 2 mg/mL), slow bactericidal activity and relatively
poor tissue penetration of vancomycin may, however,
contribute to poor performance and clinical success.12 In
case of glycopeptide treatment failure, a combined ther-
apy can be an effective medical option. In addition to the
debilitated status of our patient, her family’s unwilling-
ness to surgical intervention made antibiotic therapy the
only choice for this patient. Our case demonstrates the
effectiveness of a combination therapy comprisingglycopeptide and fosfomycin for MRSA bacteremia and
vertebral osteomyelitis.
At present, there are no definitive guidelines for the
management of vertebral osteomyelitis, discitis, and
epidural abscess. No data from randomized, controlled
trials to guide decisions about specific antimicrobial regi-
mens or duration of therapy are available.15,16 Our case
showed the clinical effectiveness of fosfomycin plus tei-
coplanin combination treatment. In addition, intramuscular
injections of teicoplanin, and oral administration of
rifampicin and fusidic acid may be a choice for long-term
maintenance therapy for outpatients and avoidance of
prolonged hospitalization.References
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